Improving Cardiometabolic Patient Outcomes
Live Internet Presentations March 3-4, 2009 from 9:30 AM to 7:00 PM (EST)
Web Enduring Material Presentations available March 5, 2009 to June 30, 2009 at www.cardiocarelive.com
Target Audience: Cardiologists, primary care physicians, endocrinologists, nurses, diabetes educators, physician assistants, pharmacists, and other healthcare professionals with expertise in the field of cardiometabolic risk factors.
The live sessions will be in the form of video webcasts with real-time Q&A from a faculty of world-renowned cardiometabolic experts. These presentations will be downloaded to the website: www.cardiocarelive.com on March 5, 2009.
Each presentation will take approximately one hour to complete. There are no prerequisites to participate.
Method of Participation: Participants will log-in, view presentation and after each lecture be presented with a post-test/ evaluation. Upon completion of the post-test /evaluation and receiving a grade of 70%, a CME certificate will be mailed within four to six weeks.
Statement of Need: The Institute of Medicine’s report, Priority Areas for National Action: Transforming Health Care Quality, identified CV risk as one of the top priority health care conditions. The difference between the present success rates in CV risk management and those thought to be achievable using the most advanced standard of care constitutes a significant health care quality gap. It has become apparent that current poor CV management rates relate largely due to both physician and patient treatment barriers. The Agency of Healthcare Research and Quality (AHRQ) report commissioned to investigate quality improvement in CV risk management recognized a number of physician-related factors that may contribute to this gap in practice. This activity will attempt to address this issue.
Learning Objectives: After attending this activity, the participant will demonstrate the ability to:
1) Improve the assessment of cardiovascular risk factors in patients,
2) Determine primary and secondary cardiovascular prevention strategies,
3) Understand the impact of such factors as ethnicity, exercise, and diet on the reduction of heart disease, and
4) Recognize the importance of a multi-disciplinary approach to cardiovascular patient care.
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.
Accreditation Statement:
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement:
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 12 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
AAFP Accreditation Statement:
This activity has been reviewed and is acceptable for up to 12.00 Elective credits by the American Academy of Family Physicians.
Acknowledgement:
We wish to acknowledge the following companies that have provided an educational grant in support of this activity: AstraZeneca
Copyright: Johns Hopkins University School of Medicine
Faculty
Johns Hopkins Program Director
Roger Blumenthal, MD, FACC., FCCP, FAHA
Professor, Department Medicine, Division of Cardiology
Director of Preventive Cardiology and
The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease
Johns Hopkins University School of Medicine
Baltimore, MD
Louis Aronne, MD
Clinical Professor, Department of Medicine
Weill Medical College of Cornell University
Adjunct Clinical Associate Professor of Medicine at Columbia University
Assistant Attending Physician at New York Presbyterian Hospital.
Director of the Comprehensive Weight Control Program
New York, New York
Christie Ballantyne, MD,
Professor, Department of Medicine and Pediatrics
Chief of Atherosclerosis and Vascular Medicine
Baylor College of Medicine
Director, Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center
Director of the Maria and Alando J. Ballantyne, M.D. Atherosclerosis Laboratory
Co-Director, Lipid Metabolism and Atherosclerosis Clinic, the Methodist Hospital in Houston
Houston, Texas
Benjamin Bluml, RPh
Vice President, Research
American Pharmacists Association Foundation
Washington, DC
Robert Eckel, MD
Professor, Department of Medicine, Division of Cardiology
University of Colorado
Denver, Colorado
Barbara Fletcher, RN, MSN, FAAN
Clinical Associate Professor - University of North Florida
Jacksonville, Florida
Gerald Fletcher, MD
Professor, Department of Medicine
Mayo Clinic College of Medicine.
Cardiovascular Specialist,- The Mayo Clinic
Jacksonville, Florida
Peter Libby, MD
Mallinckrodt Professor, Department of Medicine
Director, D.W. Reynolds Cardiovascular Clinical Research Center
Harvard Medical School
Chief of Cardiovascular Medicine
Brigham & Women's Hospital
Boston, Massachusetts
Nancy Houston Miller, RN, BSN
Associate Director
Stanford Cardiac Rehabilitation Program
Clinical Assistant Professor
University of California San Francisco (UCSF) School of Nursing
San Francisco, California
Lori Mosca, MD, MPH, PhD
Professor of Medicine
Director of Preventive Cardiology
New York-Presbyterian Hospital/Columbia University Medical Center
Director, Columbia Center for Heart Disease Medical Center
New York, New York
Richard Nesto, MD
Chairman, Department of Cardiovascular Medicine
Lahey Clinic Medical Center
Associate Professor , Department of Medicine at Harvard Medical School
Boston, Massachusetts
Clyde Yancy, MD,
Chief, Cardiothoracic Transplantation
Baylor University Medical Center
Medical Director. Baylor Heart and Vascular Institute
Baylor University Medical Center
Program Agenda
Tuesday, March 3, 2009
9:30 AM to 10:30 AM Strategies to Improve Cardiovascular Risk Prediction
Roger Blumenthal, MD
11:00 AM to 12:00 PM New Insights into the Management of Patients with Heart Failure
Clyde Yancy, MD
1:00 PM to 2:00 PM Implementation of Proper Exercise Prescriptions to Reduce
Cardiovascular Disease Risk
Gerald Fletcher, MD
2:00 PM to 3:00 PM Impact of a Multi-Disciplinary Approach to Patient Care
Barbara Fletcher, RN
4:00 PM to 5:00 PM The Nurses Role in the Care of the Cardiometabolic Patient
Nancy Houston Miller, RN
6:00 PM to 7:00 PM Update on the Clinical Utility of Biomarkers in Primary and
Secondary Prevention
Christie Ballantyne
Wednesday, March 4, 2009
9:30 AM to 10:30 AM Inflammation in Atherothrombosis: Theory and Practice
Peter Libby, MD
11:00 AM to 12:00 PM Reducing Cardiovascular Risk in Diabetes
Richard Nesto, MD
1:00 PM to 2:00 PM Weight Related Cardiovascular Risk
Louis Aronne, MD
2:00 PM to 3:00 PM Quality CVD Preventive Care: Closing the Gender Gap
Lori Mosca, MD
4:00 PM to 5:00 PM Strategies to Optimize Diet and Nutrition
Robert Eckel, MD
5:00 PM to 6:00 PM Medication Compliance
Benjamin Blumi, MD
Full Disclosure Policy Affecting CME Activities:
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Johns Hopkins University School of Medicine to require the disclosure of the existence of any relevant financial interest or any other relationship a faculty member or a provider has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following.
Louis J. Aronne, MD Grants/Research: Amylin Pharmaceuticals, Inc, Arena
Pharmaceuticals Inc., Merck & Company, Novo Nordisk, Orexigen
Therapeutics, Inc., Pfizer Inc., Schering-Plough, TransTech Pharma
Inc.
Advisory Board: Amylin Pharmaceuticals, Inc, Genaera Corp,
GI Dynamics, Inc., GlaxoSmithKline, Johnson and Johnson, Merck
& Company, NeuroSearch, Inc., Novo Nordisk, Orexigen
Therapeutics, Inc., Pfizer Inc., Sanofi-aventis, Vivus, Inc.
Ownership Interest: CardioMetabolic Support Network, LLC
Christie M. Ballantyne, MD Grants/Research/Honorarium: Abbott, AstraZeneca,
GlaxoSmithKline, Merck, Merck/Schering-Plough, Novartis, Pfizer,
Sanofi-Synthelabo, Schering-Plough, Takeda
Speaker’s Bureau: AstraZeneca, GlaxoSmithKline, Merck,
Merck/Schering-Plough, Pfizer, Reliant, Schering-Plough
